Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGYY for Male Infertility
NCT05792813Phase 1Unknown
- Sponsor
- Xiyuan Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Linggui Yangyuan Paste in male infertility, asthenozoospermia and oligoasthenozoospermia (OA) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Total progressive motile sperm count at 12 weeks. Status: unknown.
02
Drugs
Linggui Yangyuan Paste
03
Conditions
male infertilityasthenozoospermiaoligoasthenozoospermia (OA)
Beyond the preview
Go deeper on NCT05792813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792813.